Trials / Completed
CompletedNCT03554850
Trevo® Retriever Registry (China)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 201 (actual)
- Sponsor
- Stryker Neurovascular · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Trevo® Retriever Registry (China) is to assess real world performance of the FDA cleared Trevo Retriever intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke in China.
Detailed description
Trevo Registry (China) is a prospective, open-label, multi-center study, and it is the first Stryker China trial. This trial assesses real world performance of the Trevo® Retriever which is intended to restore blood flow in the neurovasculature by removing thrombus in subjects experiencing ischemic stroke. Total of 200 subjects among up to 15 sites in China local will participate in this trial. The primary endpoint is revascularization status assessment at the end of the procedure using the modified TICI score.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Trevo® Retriever | Stent retriever procedure |
Timeline
- Start date
- 2019-01-30
- Primary completion
- 2020-09-08
- Completion
- 2021-02-02
- First posted
- 2018-06-13
- Last updated
- 2022-05-27
- Results posted
- 2022-01-31
Locations
10 sites across 1 country: China
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03554850. Inclusion in this directory is not an endorsement.